Advertisement

Topics

The Medicines Company’s PCSK9 Drug Demonstrates Positive Results in Mid-Stage Study

09:59 EDT 19 Oct 2016 | Speciality Pharma Journal

PARSIPPANY, N.J.–(BUSINESS WIRE)–The Medicines Company (NASDAQ:MDCO) today announced top-line results from the interim analysis with Day 90 follow-up for all 501 patients enrolled in the ongoing ORION-1 study of PCSK9si, its investigational first-in-class PCSK9 synthesis inhibitor. Data from the interim analysis confirm the significant and durable LDL-C reduction demonstrated up to Day 90 in the …

Original Article: The Medicines Company’s PCSK9 Drug Demonstrates Positive Results in Mid-Stage Study

NEXT ARTICLE

More From BioPortfolio on "The Medicines Company’s PCSK9 Drug Demonstrates Positive Results in Mid-Stage Study"

Quick Search
Advertisement